- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01567306
Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
Phase II, Multicenter, Randomized, Double Blind Study, With Subcutaneous Immunotherapy At Different Doses, in Parallel Groups and Placebo-Controlled, in Patients With Rhinoconjunctivitis ± Asthma Sensitized to Phleum Pratense
Study Overview
Status
Conditions
Detailed Description
In adherence to EMA guidelines, the Phase I Clinical trial was carried out using Phleum pratense extract in depot presentation using 3 different dose escalation scheme. The objective was to compare tolerance and safety of the three dose escalation scheme as well as to determine the maximum dose tolerated by the population.
Once the range of tolerated doses was established, and following the strict norms of the EMA, a Phase II dose response clinical trial was designed wherein the efficacy of subcutaneous immunotherapy in depot presentation could be compared in 5 different doses. One of these doses will be the MTD established by the population in the first study, another will be lower than this dose, and three will be greater than it. The dose escalation scheme to be tested was chosen based on the results of the aforementioned clinical trial. As dictated by EMA norms, a control placebo will be used.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Coimbra, Portugal, 3000-075
- Hospital da Universidade de Coimbra
-
Porto, Portugal, 4200-319
- Centro Hospitalar de S. João
-
Senhora da Hora, Portugal, 4460-188
- Instituto CUF Porto
-
Setúbal, Portugal, 2910-446
- Centro Hospitalar de Setúbal - Hospital de São Bernardo
-
Vila Nova de Gaia, Portugal, 4434-502
- Centro Hospitalar Gaia/Espinho
-
-
-
-
-
Madrid, Spain, 28034
- Hospital Universitario Ramón y Cajal
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
Madrid, Spain, 28007
- Hospital Universitario Gregorio Maranon
-
Madrid, Spain, 28222
- Hospital Universitario Puerta De Hierro
-
-
Toledo
-
Talavera de la Reina, Toledo, Spain, 45600
- Hospital Ntra. Sra. del Prado
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must sign the Informed Consent Form.
- Patients must be between 18 and 60 years of age.
- Patients with seasonal allergic rhinoconjunctivitis produced by Phleum pratense during at least 2 years prior to participating in the study. Although the pathology being studied is allergic rhinoconjunctivitis, patients who have concomitant mild or moderate asthma may be included.
- Patients who have had a skin prick test result equal or more than 3 mm in diameter against Phleum pratense.
- Patients who have specific IgE equal or more than class 2 (CAP/PHADIA) to Phleum pratense.
Patients will preferably be monosensitized to Phleum pratense. Polysensitized patients may only be included in the study if their other sensitizations are produced by:
- Overlapping seasonal pollens which are cross-reactive with Phleum pratense.
- Pollens whose seasons do not overlap with Phleum pratense and which are not expected to produce symptoms during the study period.
- Other allergens which are not expected to produce symptoms during the study period.
- Women of child-bearing potential must have a negative urine pregnancy test at the time they begin the study.
- Furthermore, women of child-bearing potential must agree to use adequate contraceptive methods during this study if they are sexually active.
Exclusion Criteria:
- Patients with stable and continued use of allergy medication during the 2 weeks prior to their inclusion in the study.
- Patients sensitized to allergens with overlapping seasons but which are not cross-reactive with Phleum pratense and with specific IgE levels equal or less than class 2 CAP/PHADIA.
- Patients who have received immunotherapy in the 5 years prior to the study against either the allergen being tested or an allergen which is cross-reactive, or who are currently receiving immunotherapy for any other allergen.
- Patients with severe asthma or FEV1 < 70% or with asthma which requires treatment with inhaled or systemic corticoids at the time of the study or in the 8 weeks immediately prior to the onset of treatment.
- Patients with immunological, cardiac, renal or hepatic diseases or any with any other illness which the investigators deem may interfere with the study.
- Patients with a prior history of anaphylaxis.
- Patients with chronic urticaria.
- Patients with moderate-severe atopic dermatitis.
- Patients with clinically relevant malformations of the upper respiratory tract.
- Patients who have participated in another clinical trial within 3 months prior to this study.
- Patients being treated with tricyclic antidepressants, psychotropic drugs, beta-blockers, or angiotensin-converting enzyme inhibitors (ACEIs).
- Women who are pregnant or breast-feeding or are of child-bearing age and who do not agree to use adequate contraception if they are sexually active and who have not demonstrated that they have been surgically sterilized or have other means of not bearing children.
- Patients who cannot attend study visits.
- Patients who are uncooperative or refuse to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Allergovac Depot Group 1 Active
|
Increasing dosages till the maintenance dose of 0.25 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 0.5 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 1SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 2 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 4SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
|
Experimental: Allergovac Depot Group 2 Active
|
Increasing dosages till the maintenance dose of 0.25 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 0.5 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 1SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 2 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 4SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
|
Experimental: Allergovac Depot Group 3 Active
|
Increasing dosages till the maintenance dose of 0.25 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 0.5 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 1SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 2 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 4SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
|
Experimental: Allergovac Depot Group 4 Active
|
Increasing dosages till the maintenance dose of 0.25 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 0.5 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 1SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 2 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 4SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
|
Experimental: Allergovac Depot Group 5 Active
|
Increasing dosages till the maintenance dose of 0.25 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 0.5 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 1SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 2 SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
Increasing dosages till the maintenance dose of 4SPT is reached.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
|
Placebo Comparator: Placebo - Group 6
|
Increasing volumes of placebo.
Afterwards, 3 maintenance doses are given at 4-weekly intervals.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Variation of the Concentration of Phleum Pratense Extract Needed to Produce a Positive Nasal Provocation Test From Baseline (V0) to Final Visit (FV).
Time Frame: Baseline (V0) and Final Visit (FV). The Final Visit will be conducted within 7 plus minus 2 days after the last dose is administered. The study will be carried out outside the pollination season of Phleum pratense.
|
Variation of the concentration of Phleum pratense extract needed to produce a positive nasal provocation test from baseline (V0) to final visit (FV).
The changes will be compared among groups (including the placebo group).
|
Baseline (V0) and Final Visit (FV). The Final Visit will be conducted within 7 plus minus 2 days after the last dose is administered. The study will be carried out outside the pollination season of Phleum pratense.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All Adverse Reactions and or Events Will be Recorded Both by the Patient and the Health Care Personnel Responsible for the Administration of the Subcutaneous Immunotherapy.
Time Frame: From baseline (V0) to final visit (VF). The Final Visit will be conducted within 7 plus minus 2 days after the last dose is administered. All AE should be monitored until they are satisfactorily resolved or stabilized after the final visit of the study
|
All adverse reactions and/or events were recorded both by the patient and the health care personnel responsible for the administration of the subcutaneous immunotherapy.
The incidence and intensity of adverse events was compared among the treatment groups.
|
From baseline (V0) to final visit (VF). The Final Visit will be conducted within 7 plus minus 2 days after the last dose is administered. All AE should be monitored until they are satisfactorily resolved or stabilized after the final visit of the study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Emilio Alvarez Cuesta, MD, Hospital Universitario Ramón y Cajal
- Principal Investigator: Santiago Quirce, MD, Hospital Universitario La Paz
- Principal Investigator: Matilde Rodríguez, MD, Hospital Universitario Puerta De Hierro
- Principal Investigator: Carmen Panizo, MD, Hospital Ntra. Sra. del Prado
- Principal Investigator: João Fonseca, MD, Instituto CUF Porto
- Principal Investigator: José Luís Plácido, MD, Centro Hospitalar de S. João
- Principal Investigator: José Alberto Ferreira, MD, Centro Hospitalar Gaia/Espinho
- Principal Investigator: Celso Pereira, MD, Hospital da Universidade de Coimbra
- Principal Investigator: Filipe Inácio, MD, Centro Hospitalar de Setúbal - Hospital de São Bernardo
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BIA-PHL-P2-001
- 2011-000814-21 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Rhinoconjunctivitis
-
ALK-Abelló A/SCompletedAllergic RhinoconjunctivitisSpain
-
ALK-Abelló A/SCompletedAllergic RhinoconjunctivitisSpain
-
Immunomic Therapeutics, Inc.CompletedAllergic RhinoconjunctivitisUnited States
-
ALK-Abelló A/SCompleted
-
Medical University of GrazRecruiting
-
Immunomic Therapeutics, Inc.Completed
-
University of ZurichCompletedAllergic RhinoconjunctivitisSwitzerland
-
Cytos Biotechnology AGCompletedHouse Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis
-
Cytos Biotechnology AGCompletedHouse Dust Mite Allergy | Perennial Allergic RhinoconjunctivitisSwitzerland
-
ClinNovis GmbHCompletedRhinoconjunctivitis, AllergicGermany
Clinical Trials on Allergovac Depot
-
Roxall Medicina España S.ACompletedAllergic RhinoconjunctivitisSpain
-
Roxall Medicina España S.ACompleted
-
Roxall Medicina España S.ACompleted
-
Roxall Medicina España S.ACompleted
-
Roxall Medicina España S.ACompletedAsthma | Allergic Rhinitis | RhinoconjunctivitisSpain
-
Roxall Medicina España S.ACompleted
-
Roxall Medicina España S.ARecruitingAllergy to Himenoptera VenomSpain
-
Roxall Medicina España S.ACompletedRhinitis, Allergic | RhinoconjunctivitisSpain
-
Medical University of LodzUnknown
-
BioromaUnknownOvarian Hyperstimulation Syndrome | Polycystic Ovarian Syndrome | Invitro FertilizationItaly